Authors’ reply: Inadequate analysis of the budgetary impact of new label indications after initial drug registration in Brazil: A response to a published case study

Marcus Carvalho Borin^1,2*, Mariana Michel Barbosa^1,2, Camila Oliveira Pereira^1,2, Carina Rejane Martins¹, Daniel Pitchon dos Reis¹, Geraldo José Coelho Ribeiro^1,3, Júlia Teixeira Tupinambás¹, Karina de Castro Zocrato¹, Lélia Maria de Almeida Carvalho¹, Marcela Pinto de Freitas¹, Maria da Glória Cruvinel Horta¹, Mariza Cristina Torres Talim¹, Ernesto Gomes de Azevedo¹, Sergio Adriano Loureiro Bersan¹, Silvana Marcia Bruschi Kelles^1,3

Show Less

¹ Unimed-BH, Health Technology Assessment Group, Belo Horizonte, Minas Gerais, Brazil

² Department of Social Pharmacy, Federal University of Minas Gerais (UFMG), Faculty of Pharmacy, Belo Horizonte, Minas Gerais, Brazil

³ Department of Medicine, Pontifical Catholic University of Minas Gerais, Institute of Biological and Health Sciences, Betim, Minas Gerais, Brazil

GHES, 4439 https://doi.org/10.36922/ghes.4439

Submitted: 5 August 2024 | Accepted: 14 August 2024 | Published: 23 September 2024

© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Conflict of interest

The authors declare that they have no competing interests.

References

ANS Realiza a 30^aReunião Técnica da Cosaúde. (n.d.). Agência Nacional de Saúde Suplementar. Available from: https:// www.gov.br/ans/pt-br/assuntos/noticias/sociedade/ans-realiza-a-30a-reuniao-tecnica-da-cosaude [Last accessed on 2024 Jul 30].

Bero, L. (2017). Addressing Bias and conflict of interest among biomedical researchers. JAMA, 317(17):1723-1724. https://doi.org/10.1001/jama.2017.3854

Cruz, J.A.W., da Cunha, M.A.V.C., de Moraes, T.P., Marques, S., Tuon, F.F., Gomide, A.L., et al. (2022). Brazilian private health system: History, scenarios, and trends. BMC Health Services Research, 22(1):49. https://doi.org/10.1186/s12913-021-07376-2

INCA. (2022). INCA Estima 704 Mil Casos de Câncer Por Ano No Brasil Até 2025. Instituto Nacional de Câncer - INCA. Available from: https://www.gov.br/inca/pt-br/assuntos/ noticias/2022/inca-estima-704-mil-casos-de-cancer-por-ano-no-brasil-ate-2025 [Last accessed on 2024 Jul 30].

Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Jesus-Acosta, A., Delord, J.P., et al. (2020). Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 38(1):1-10. https://doi.org/10.1200/JCO.19.02105

NICE. (2024). NICE Disappointed Companies Unwilling to Offer Fair Price to Make Enhertu Available for Advanced Breast Cancer. NICE. Available from: https://www.nice. org.uk/news/articles/nice-disappointed-that-companies-unwilling-to-offer-fair-price-to-the-nhs-to-make-enhertu-available [Last accessed on 2024 Jul 30].

Riveros, B.S., Cavalcanti, M.G., Leonart, L.P., Rosim, M.P., Almeida, A.B., & Licursi, C.A. (2024). Budgetary impact of new label indications after initial drug registration in Brazil: A case study of pembrolizumab and trastuzumab deruxtecan. Global Health Economics and Sustainability, 2(1):1889. https://doi.org/10.36922/ghes.1889

Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Caro, J.J., Lee, K.M., Minchin, M., et al. (2014). Budget impact analysis-principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force. Value in Health, 17(1):5-14. https://doi.org/10.1016/j.jval.2013.08.2291

Previous article in this issue

Next article in this issue

Global Health Economics and Sustainability, Electronic ISSN: 2972-4570 Published by AccScience Publishing